Modality
Nanobody
MOA
PCSK9i
Target
LAG-3
Pathway
Complement
MM
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
Jul 2017
→ Jul 2029
Phase 2Current
NCT05695638
2,743 pts·MM
2017-07→2029-07·Not yet recruiting
NCT08738356
530 pts·MM
2024-06→TBD·Completed
3,273 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-093.3y awayPh2 Data· MM
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Not yet…
P2
Complet…
Catalysts
Ph2 Data
2029-07-09 · 3.3y away
MM
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05695638 | Phase 2 | MM | Not yet recr... | 2743 | Mayo |
| NCT08738356 | Phase 2 | MM | Completed | 530 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| Capicilimab | Structure Ther | Phase 1 | EGFR |